{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=high+in-degree&page=2",
    "query": {
      "intervention": "high in-degree",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=high+in-degree&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T03:01:06.302Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05455294",
      "title": "Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myeloid Malignancy",
        "Myelodysplastic Syndromes",
        "Myelofibrosis",
        "Acute Myeloid Leukemia",
        "Myeloproliferative Neoplasm"
      ],
      "interventions": [
        {
          "name": "Navitoclax",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jacqueline Garcia, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2022-07-18",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-09-30T03:01:06.302Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05455294"
    },
    {
      "nct_id": "NCT01729845",
      "title": "Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Previously Treated Myelodysplastic Syndrome",
        "Recurrent Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mitoxantrone Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2012-12-20",
      "completion_date": "2017-04-03",
      "has_results": true,
      "last_update_posted_date": "2019-02-07",
      "last_synced_at": "2026-09-30T03:01:06.302Z",
      "location_count": 3,
      "location_summary": "Kennewick, Washington • Kirkland, Washington • Seattle, Washington",
      "locations": [
        {
          "city": "Kennewick",
          "state": "Washington"
        },
        {
          "city": "Kirkland",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01729845"
    },
    {
      "nct_id": "NCT07723703",
      "title": "Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukaemia",
        "High Risk Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "AMX-883",
          "type": "DRUG"
        },
        {
          "name": "Posaconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amphista Therapeutics Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2026-09-30",
      "completion_date": "2029-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-09-30T03:01:06.302Z",
      "location_count": 1,
      "location_summary": "Fairfax, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07723703"
    },
    {
      "nct_id": "NCT05819541",
      "title": "Treating Exacerbations of Asthma With Oral Montelukast in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Status Asthmaticus"
      ],
      "interventions": [
        {
          "name": "Montelukast Oral Granules",
          "type": "DRUG"
        },
        {
          "name": "Albuterol",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "4 Years to 12 Years"
      },
      "enrollment_count": 90,
      "start_date": "2023-10-20",
      "completion_date": "2026-03-26",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-09-30T03:01:06.302Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05819541"
    },
    {
      "nct_id": "NCT00613054",
      "title": "Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "Zactima, Gleevec, Hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Annick Desjardins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2007-11",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2012-12-05",
      "last_synced_at": "2026-09-30T03:01:06.302Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00613054"
    },
    {
      "nct_id": "NCT07113067",
      "title": "Accelerated rTMS vs. Sham for Stroke Apathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Apathy",
        "Stroke",
        "Stroke Sequelae",
        "Stroke/Brain Attack",
        "Stroke/ Cerebrovascular Accident (Ischemic or Hemorrhagic)",
        "Motivation",
        "Abulia"
      ],
      "interventions": [
        {
          "name": "MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active)",
          "type": "DEVICE"
        },
        {
          "name": "MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Sham)",
          "type": "DEVICE"
        },
        {
          "name": "Brainsight Neuronavigation System",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2025-08-08",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-09-30T03:01:06.302Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07113067"
    },
    {
      "nct_id": "NCT07794631",
      "title": "Strategies to Transform Kidney Care and Improve Pursuit of Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Kidney Disease",
        "Kidney Transplant",
        "Deceased Donor Kidney Transplant",
        "Living Donor Kidney Transplantation",
        "Chronic Kidney Disease (Stages 3b-5)"
      ],
      "interventions": [
        {
          "name": "Digital Health Integration",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Training for Early Transplant Access and Support",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Kidney Health Mobile Health (mHealth) Application",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5000,
      "start_date": "2022-08-15",
      "completion_date": "2027-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-09-30T03:01:06.302Z",
      "location_count": 1,
      "location_summary": "Pasadena, California",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07794631"
    },
    {
      "nct_id": "NCT00005835",
      "title": "N99-02: Melphalan and Buthionine Sulfoximine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "buthionine sulfoximine",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "Peripheral blood stem cell infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Filgrastim",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "New Approaches to Neuroblastoma Therapy Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 31,
      "start_date": "2001-08",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2023-04-10",
      "last_synced_at": "2026-09-30T03:01:06.302Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • San Francisco, California • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005835"
    },
    {
      "nct_id": "NCT04999384",
      "title": "First in Human, Dose Escalation Study of AN4005",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Advanced Lymphoma"
      ],
      "interventions": [
        {
          "name": "AN4005-dose level 0",
          "type": "DRUG"
        },
        {
          "name": "AN4005-dose level 1",
          "type": "DRUG"
        },
        {
          "name": "AN4005-dose level 2",
          "type": "DRUG"
        },
        {
          "name": "AN4005-dose level 3",
          "type": "DRUG"
        },
        {
          "name": "AN4005-dose level 4",
          "type": "DRUG"
        },
        {
          "name": "AN4005-food effect",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adlai Nortye Biopharma Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2021-09-27",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-09-30T03:01:06.302Z",
      "location_count": 4,
      "location_summary": "Hackensack, New Jersey • The Bronx, New York • Greenville, South Carolina + 1 more",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04999384"
    },
    {
      "nct_id": "NCT05298358",
      "title": "RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "RIC alloBMT w PTCy in refractory SSc",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1,
      "start_date": "2022-11-18",
      "completion_date": "2024-11-21",
      "has_results": false,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-09-30T03:01:06.302Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05298358"
    }
  ]
}